BAD HOMBURG, Germany--(BUSINESS WIRE)--April 12, 2005--Fresenius Medical Care AG (“the Company”) (Frankfurt Stock Exchange: FME, FME3) (NYSE: FMS, FMS-p), the world’s largest provider of Dialysis Products and Services, today announced that it has received U.S. FDA (Food and Drug Administration), 510(k) clearance for an advanced device to be used by patients who perform dialysis in the home setting. This proprietary device, the Liberty(TM) Cycler, is designed for use in Automated Peritoneal Dialysis (APD) therapy, which is the fastest growing home therapy for the treatment of end-stage renal disease (ESRD). Receipt of the 510(k) indicates that the Liberty(TM) Cycler has met the requirements for notifying the FDA prior to commercial distribution of new medical devices and that Fresenius Medical Care may market this device within the United States.
